Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.
News|Videos|October 21, 2024
[Sponsored Content] Patient Engagement Throughout the Entire Product Lifecycle
Author(s)Reverba Global
In the pharmaceutical industry, patient engagement should be centered in health education, communication, and strategy during drug discovery and throughout the product lifecycle. Cheryl Lubbert, CEO of Reverba, discusses the importance of a patient-first mindset in the industry.
Related to this article
With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
Ignite Proteomics measures phosphorylation states to show which proteins are actively driving a tumor—guiding therapy beyond what IHC alone reveals.
When tumors shift, old treatments stop working. Dr. Brian Corgiat explains why real-time tumor profiling is critical to effective therapy.
Dr. Brian Corgiat makes the case for phosphoproteome testing—measuring what’s actively driving a tumor right now, not just static mutations.
Ignite Proteomics’ Dr. Brian Corgiat explains why tumors change over time—and why treatment must adapt to the current tumor, not the original.
Trending on PharmExec
1
Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site
2
Building Connected AI Ecosystems, Not Standalone Tools
3
Where AI Is Having the Most Impact and Where Gaps Remain
4
FDA Pauses Commissioner’s National Priority Voucher Program: Report
5